CRVS CORVUS PHARMACEUTICALS INC revenue, earnings and financials
For the quarter ended June 30, 2026, CORVUS PHARMACEUTICALS INC reported revenue of n/a, net income of −$18.0M and diluted EPS of −$0.19; for the fiscal year ended December 2025 revenue was n/a.
CRVS annual revenue and earnings
- Fiscal year ended Dec 2025: revenue n/a, gross profit n/a, operating income −$43.0M, net income −$15.3M (margin n/a), EPS −$0.53
- Fiscal year ended Dec 2024: revenue n/a, gross profit n/a, operating income −$27.5M, net income −$62.3M (margin n/a), EPS −$1.02
- Fiscal year ended Dec 2023: revenue n/a, gross profit n/a, operating income −$23.4M, net income −$27.0M (margin n/a), EPS −$0.56
- Fiscal year ended Dec 2022: revenue n/a, gross profit n/a, operating income −$32.6M, net income −$41.3M (margin n/a), EPS −$0.89
- Fiscal year ended Dec 2021: revenue n/a, gross profit n/a, operating income −$38.6M, net income −$43.2M (margin n/a), EPS −$1.03
CRVS quarterly revenue and earnings
- Quarter ended Jun 30, 2026: revenue n/a, net income −$18.0M, EPS −$0.19
- Quarter ended Mar 31, 2026: revenue n/a, net income −$13.7M, EPS −$0.15
- Quarter ended Dec 31, 2025 (from the annual report): revenue n/a, net income −$12.3M, EPS −$0.18
- Quarter ended Sep 30, 2025: revenue n/a, net income −$10.2M, EPS −$0.12
- Quarter ended Jun 30, 2025: revenue n/a, net income −$8.00M, EPS −$0.10
- Quarter ended Mar 31, 2025: revenue n/a, net income $15.2M, EPS −$0.13
- Quarter ended Dec 31, 2024 (from the annual report): revenue n/a, net income −$12.1M, EPS −$0.23
- Quarter ended Sep 30, 2024: revenue n/a, net income −$40.2M, EPS −$0.60
- Quarter ended Jun 30, 2024: revenue n/a, net income −$4.26M, EPS −$0.07
- Quarter ended Mar 31, 2024: revenue n/a, net income −$5.70M, EPS −$0.12
- Quarter ended Dec 31, 2023 (from the annual report): revenue n/a, net income −$6.62M, EPS −$0.13
- Quarter ended Sep 30, 2023: revenue n/a, net income −$6.00M, EPS −$0.12
- Quarter ended Jun 30, 2023: revenue n/a, net income −$6.50M, EPS −$0.14
- Quarter ended Mar 31, 2023: revenue n/a, net income −$7.87M, EPS −$0.17
- Quarter ended Dec 31, 2022 (from the annual report): revenue n/a, net income −$9.82M, EPS −$0.21
- Quarter ended Sep 30, 2022: revenue n/a, net income −$14.8M, EPS −$0.32
- Quarter ended Jun 30, 2022: revenue n/a, net income −$8.36M, EPS −$0.18
- Quarter ended Mar 31, 2022: revenue n/a, net income −$8.30M, EPS −$0.18
- Quarter ended Dec 31, 2021 (from the annual report): revenue n/a, net income −$9.24M, EPS −$0.20
- Quarter ended Sep 30, 2021: revenue n/a, net income −$10.7M, EPS −$0.24
CRVS cash flow, buybacks and dividends
- Fiscal year ended Dec 2025: operating cash flow −$32.8M, share buybacks n/a
- Fiscal year ended Dec 2024: operating cash flow −$25.4M, share buybacks n/a
- Fiscal year ended Dec 2023: operating cash flow −$23.9M, share buybacks n/a
- Fiscal year ended Dec 2022: operating cash flow −$27.0M, share buybacks n/a
- Fiscal year ended Dec 2021: operating cash flow −$36.7M, share buybacks n/a
CRVS balance sheet
- Jun 30, 2026: cash $18.9M, total assets $239M, total liabilities $13.9M, shareholders' equity $225M
- Mar 31, 2026: cash $40.1M, total assets $253M, total liabilities $12.5M, shareholders' equity $241M
- Dec 31, 2025: cash $4.58M, total assets $71.1M, total liabilities $9.91M, shareholders' equity $61.2M
- Sep 30, 2025: cash $2.87M, total assets $80.5M, total liabilities $8.71M, shareholders' equity $71.8M
- Jun 30, 2025: cash $14.7M, total assets $89.5M, total liabilities $9.23M, shareholders' equity $80.2M
- Mar 31, 2025: cash $5.00M, total assets $59.4M, total liabilities $10.1M, shareholders' equity $49.3M
- Dec 31, 2024: cash $8.74M, total assets $68.9M, total liabilities $36.3M, shareholders' equity $32.6M
- Sep 30, 2024: cash $4.68M, total assets $58.8M, total liabilities $46.4M, shareholders' equity $12.4M
Is CRVS profitable?
No. CORVUS PHARMACEUTICALS INC lost $54.1M over the last four quarters.
What is CRVS's EPS?
Diluted earnings per share over the last four quarters were −$0.64; −$0.19 in the latest quarter.